Compare RDVT & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDVT | LXRX |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.9M | 660.9M |
| IPO Year | 2017 | 2000 |
| Metric | RDVT | LXRX |
|---|---|---|
| Price | $38.98 | $1.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $62.00 | $4.15 |
| AVG Volume (30 Days) | 100.2K | ★ 2.2M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.00 | 77.78 |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $90,252,000.00 | $49,803,000.00 |
| Revenue This Year | $16.31 | N/A |
| Revenue Next Year | $13.83 | N/A |
| P/E Ratio | $40.54 | ★ N/A |
| Revenue Growth | 20.03 | ★ 60.24 |
| 52 Week Low | $33.40 | $0.49 |
| 52 Week High | $64.14 | $1.84 |
| Indicator | RDVT | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.66 | 63.86 |
| Support Level | $35.84 | $1.07 |
| Resistance Level | $39.63 | N/A |
| Average True Range (ATR) | 1.90 | 0.10 |
| MACD | 0.46 | 0.01 |
| Stochastic Oscillator | 89.41 | 98.57 |
Red Violet Inc builds proprietary technologies and applies analytical capabilities to deliver identity intelligence. The company's solutions enable the real-time identification and location of people, businesses, assets, and their interrelationships. These solutions are used for purposes including identity verification, risk mitigation, due diligence, fraud detection and prevention, regulatory compliance, and customer acquisition. Its cloud-native, AI-enabled identity intelligence platform, CORE, is purpose-built for the enterprise, yet flexible enough for organizations of all sizes, bringing clarity to massive datasets by transforming data into intelligence. The company generates substantially all of its revenue from licensing its solutions.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.